DOES DOXORUBICIN CONTAINING CHEMOTHERAPY CHANGE METABOLIC LIVER FUNCTION DURING TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA?

J. Kolarović ,
J. Kolarović

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Konstantinidis ,
N. Konstantinidis

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Kaćanski ,
N. Kaćanski

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

J. Katanić
J. Katanić

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

Published: 01.01.2011.

Volume 39, Issue 1 (2011)

pp. 33-37;

https://doi.org/10.70949/pramed201101393K

Abstract

Doxorubicin is antitumor antibiotic extensively metabolized in the liver, and liver antioxidant capacity, including that provided by glutathione production. The aim of this study was to investigate whether doxorubicin containing chemotherapy changes metabolic liver function during treatment of childhood acute lymphoblastic leukaemia. Total protein concentration in serum, concentration of total, conjugated and non conjugated bilirubin, activity of aspartat aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (ãGT), lactate dehydrogenase and creatin kinase activity were measured before and after treatment with doxorubicin containing chemotherapy and in the control group. Caffeine was applied as metabolic marker via controlled consummation of Coca-Cola and 8-hour urine was collected immediately afterwards. In the collected samples, urinary thioethers and caffeine metabolites concentrations were measured. Chemotherapeutic regiment established for initial treatment of childhood ALL containing prednisone, vincristine, doxorubicin and L-asparaginase did not alter metabolic liver function. This regiment did not change liver enzyme activity. Applied chemotherapy also did not alter caffeine biotransformation, but it did increase urinary thioethers excretion. 

Keywords

References

1.
Cvetković P, Stojimirović E, Janić D. Treatment of acute lymphoblastic leukemia: The results of YU 0184 and 0187 protocols. Bilt Hematol. 23(1–2):43–6.
2.
M MK, JC S, JK M. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res. 19:1030–7.
3.
Al-Tonbary Y, Al-Haggar M, El-Ashry R. Vitamin E and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia. Adv Hematol. 2009.
4.
Cvetković P. Akutne limfoblastne leukemije non-B.
5.
Aviles A, Herrera J, Ramos E. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med. 108:912–3.
6.
Borota R, Lučić A. Priručnik praktičnih i seminarskih vežbi iz patološke fiziologije. In: Univerzitet u Novom Sadu, Medicinski fakultet.
7.
Summer KH, Rozman K, Coulston F, Greim H. Urinary excretion of mercapturic acids in chimpanzees and rats. Toxicol Appl Pharmacol. 50:207–12.
8.
Carillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther. 55(3):293–304.
9.
Tietz NW. Osnovi kliničke hemije.
10.
Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3-chloroethyl-nitrosourea (BCNU. Biochem Pharmacol. 32:1383–8.
11.
Burg AW. Physiological disposition of caffeine. Drug Metab Rev. 4:199–228.
12.
Kalow W, Campbell M. Biotransformation of caffeine by microsomes. ISI Atlas Sci Pharmacol. 2:381–6.
13.
Berthou F, Guillos B, Riche Z, Dreano E, Jacqz-Aigrain E, Beaune PH. Interspecies variation in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica. 22(6):671–80.
14.
Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P450 PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA. 86:769–70.
15.
Silverman K. Withdrawal syndrome after double-blind cessation of caffeine consumption. N Engl J Med. 327(1109).
16.
King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 6(2):162–76.
17.
Droz J, Cvitkovic E, Armand J, Khoury Y. Handbook of Chemotherapy in Clinical Oncology.
18.
Goodman. Gilman’s The Pharmacological Basis of Therapeutics.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by